---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-096950"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2025-07-18T23:59:59+00:00"
generated_at: "2026-05-18T05:49:21.684410+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics extends $7M license fee payment from WY Biotech to Sept 30, 2025

## Summary
- WY Biotech completed due diligence and elected to continue exclusive license agreement with HCW Biologics.
- WY Biotech's obligation includes a $7.0 million upfront license fee, originally due earlier.
- Parties agreed to extend payment deadline; confirmation of wire transfer expected on or before Sept 30, 2025.
- Amendment accommodates WY Biotech's timing for finalizing CDMO and investor agreements.

## SEC filing metadata
- accession: 0000950170-25-096950
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2025-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000095017025096950/0000950170-25-096950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000095017025096950/hcwb-20250714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-096950
- JSON: https://secwatch.observer/filing/0000950170-25-096950.json
- Plain text: https://secwatch.observer/filing/0000950170-25-096950.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.